Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Acies Bio and Protein Evolution Announce Strategic Partnership to Advance…
Protein Evolution, a pioneer in enzyme-driven plastics recycling, has announced a collaboration withAcies Bio, an innovative biotechnology company specializing in microbial R&D and biomanufacturing. This partnership aims to leverage Acies Bio's state-of-the-art SmartRoute ™ platform to scale the production of Protein Evolution's plastic-degrading enzymes, bringing the world one step closer to a future free from plastic waste.Through the SmartRoute ™ platform, Acies Bio will...
Nasdaq GlobeNewswire
21/11/2024
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial…
uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy ( MTLE ).“The dosing of the first patient in our Phase I/II trial in temporal lobe epilepsy represents an important milestone for uniQure and our third clinical trial initiation over the past...
Nasdaq GlobeNewswire
21/11/2024
Zymeworks Announces Participation in Upcoming Investor Conferences
Piper Sandler 36 thAnnual Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and present on December 3 at 1:30 pm Eastern Time (ET) in New York, NY.Citi's 2024 Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a panel discussion titled: 'Novel Antibody Mechanisms in Oncology' on December 3 at 3:15 pm ET in Miami, FL.7 thAnnual Evercore HealthCONx Conference: Zymeworks' management will participate in...
Nasdaq GlobeNewswire
21/11/2024
Outcomes4Me and the National Comprehensive Cancer Network (NCCN) Expand…
BOSTON, Nov. 21, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first direct-to-patient, personalized, and evidence-based cancer navigation platform, and the National Comprehensive Cancer Network® (NCCN®) announced today that Outcomes4Me has newly integrated the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer into its free, consumer-grade, direct-to-patient platform. BOSTON , Nov. 21, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer...
PR Newswire
21/11/2024
H.I.G. Capital Announces the Sale of Deenova S.r.l.
Since its initial investment, H.I.G. has supported Deenova's international growth through strategic acquisitions and the strengthening of its management team. The Company has become an industry leader throughout Europe, with a current presence in approximately 100 hospitals in Italy, France, United Kingdom, Malta, Germany, Spain, and Poland. Since its initial investment, H.I.G. has supported Deenova's international growth through strategic acquisitions and the strengthening of its management...
PR Newswire
21/11/2024
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of…
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial$25M milestone payment to be received from Jazz Pharmaceuticals in relation to the FDA approval; Zymeworks remains eligible for up to $500M in...
Nasdaq GlobeNewswire
21/11/2024
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
"The launch of MSK-IMPACT® powered with SOPHiA DDM™ is another major milestone in our journey to expand access to precision oncology globally and demonstrates our commitment to democratizing data-driven medicine," said Philippe Menu, M.D., PhD., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS. "Following the successful launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, we are incredibly excited to further build on our excellent collaboration with…
PR Newswire
21/11/2024
3Shape A/S and Medit Corp. Reach Settlement in Patent Infringement Lawsuit
"3Shape is pleased to have resolved this matter and move forward without further litigation," said Henriette Stakemann, 3Shape General Counsel. "Our focus remains on protecting our intellectual property while continuing to innovate and deliver value to our customers." "3Shape is pleased to have resolved this matter and move forward without further litigation," saidHenriette Stakemann, 3Shape General Counsel. "Our focus remains on protecting our intellectual…
PR Newswire
21/11/2024
New Alliance for the Development of a Sublingual Oxytocin Formulation to Prevent…
This problem, characterized by excessive bleeding after childbirth, is one of the leading causes of maternal mortality worldwide, according to the World Health Organization (WHO). Currently, it is estimated to affect approximately 14 million women each year and causes around 70,000 deaths, mostly in low- and middle-income countries. With the implementation of this sublingual treatment, many lives could be saved and provide a practical and accessible solution for the management of postpartum…
PR Newswire
21/11/2024
Philips unveils next-generation BlueSeal helium-free MRI system, integrated with…
Industry's first wide bore, high-performance helium-free [1] 1.5T MR features AI assistance at every step in the MRI workflow, with seamless integration of cloud-based AI image reading and reporting tools on the MR scanner Philips BlueSeal helium-free magnet combined with compact and lightweight design allows flexibility of installations in difficult and remote locations to improve wider access to advanced MRIPhilips' award-winning [2] AI-based SmartSpeed image reconstruction...
Nasdaq GlobeNewswire
21/11/2024
SHL Medical announces plans to establish SHL Advantec
SHL Medical's existing tooling and automation operations will be integrated into SHL Advantec, bringing their range of technologies, services, and equipment portfolio to the new business. Together with SHL Medical's recent strategic acquisitions – Swiss-based LCA Automation and SMC Mould Innovation and US-based Superior Tooling – SHL Advantec will form a global operations network spanning three continents to deliver faster support and shorter supply chain services to SHL Advantec's diverse…
PR Newswire
21/11/2024
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board…
Moncef Slaoui, PhD, and Khurem Farooq join the Board of Directors, effective immediately. Both bring vast experience in vaccine development and biopharmaceutical leadership. Moncef Slaoui, PhD, and Khurem Farooq join the Board of Directors, effective immediately. Both bring vast experience in vaccine development and biopharmaceutical leadership. Emmanuel Hanon, Chief Executive Officer of Vicebio, said: "In connection with our significant Series B financing, we are building upon our...
PR Newswire
21/11/2024
RSNA 2024 spotlight: Sectra showcases how radiologists can gain increased…
In booth #8113, Sectra will showcase its complete enterprise imaging portfolio comprised of diagnostic modules (radiology, cardiology, pathology, orthopaedics, ophthalmology and genomics), with its VNA and 'Best in KLAS PACS' at its core — all delivered as a software-as-a-service. In booth #8113, Sectra will showcase its complete enterprise imaging portfolio comprised of diagnostic modules (radiology, cardiology, pathology, orthopaedics, ophthalmology and genomics), with its VNA and 'Best in...
PR Newswire
21/11/2024
Dreame launches Black Friday deals with up to £350 off
The X40 Ultra Complete offers exceptional cleaning efficiency in even the tightest spaces around the home. With Dreame's Mop Extend™ RoboSwing Technology and extendable side brush, the robot vacuum can remove dirt from under low furniture and in hard-to-reach corners, as deep as 4cm. It also has 12,000Pa Vormax™ Suction, swiftly lifting debris with fewer passes on hard floors and carpets. The X40 Ultra Complete offers exceptional cleaning efficiency in even the tightest spaces around the home...
PR Newswire
21/11/2024
BioWorld by Clarivate Highlights Gaps in Women's Health Research and Investment…
Women make up half of the global population, yet their health remains consistently underserved. Research and treatments have traditionally focused on reproduction and breast health, but these areas represent just a fraction of the broader health challenges women face. From autoimmune disorders to cardiovascular disease, many conditions disproportionately affect women or manifest differently than in men. However, decades of research have excluded women from clinical trials, often due to…
PR Newswire
21/11/2024
KFSHRC Madinah's Virtual Clinics Wins Award at PX Congress
Post-discharge virtual visits increased 155% from 2023 RIYADH, Saudi Arabia, Nov.20, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Madinah has been honoured with the Innovative Patient Care Solutions Award at the PX Congress 2024, held in Riyadh.Madinah's Nursing Affairs won the award for its Nurse-Led Post-Discharge Care Virtual Clinics, which exceeded targets with over 5,800 post-discharge virtual visits in 2024 (an increase of 155% from...
Nasdaq GlobeNewswire
21/11/2024
IBA Business Update – Third Quarter 2024
Louvain-la-Neuve, Belgium, 21 November 2024- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2024.Group OverviewSolid equipment order intake at period-end of EUR 171 million, an increase from last year. Post-period, several major contracts finalized in Industrial Solutions to bring year to date order intake to EUR 215 millionStrong backlog conversion in the third...
Nasdaq GlobeNewswire
21/11/2024
DSM-Firmenich AG sold all of its stake in Robertet S.A.
For more information, please contact: For more information, please contact: dsm-firmenich investor relations enquiries:Email:
[email protected]
dsm-firmenich media enquiries:Email:
[email protected]
About dsm-firmenich As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With our comprehensive range of solutions,...
PR Newswire
21/11/2024
Novartis upgrades mid-term guidance and highlights deep pipeline in core…
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+ peak sales potential and 15+ near-term submission-enabling readouts 30+ high-value medicines in the pipeline expected to support continued mid-single digit sales growth beyond 2029 Basel, November 21, 2024– Today Novartis announced an upgrade to its mid-term guidance, in…
Nasdaq GlobeNewswire
21/11/2024
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing…
As per DelveInsight analysis, in 2023 the 12-month prevalent cases of chronic cough in the 7MM were estimated to be approximately 30 million cases, out of which the US accounted for nearly 13 million cases. These cases are expected to increase during the forecast period (2024–2034) driven by the aging population that has an increased likelihood of developing chronic conditions such as asthma, chronic obstructive pulmonary disease, and chronic cough. As per DelveInsight analysis, in 2023 the...
PR Newswire
20/11/2024
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nyxoah to Participate in the Piper Sandler 36 thAnnual Healthcare ConferenceMont-Saint-Guibert, Belgium – November 20, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Piper Sandler 36 thAnnual Healthcare Conference on Wednesday,...
Nasdaq GlobeNewswire
20/11/2024
Innocan Pharma Reports Third Quarter 2024 Financial Results
Financial Highlights Financial Highlights Management Comments Iris Bincovich, the CEO of Innocan commented : "As our results for both the third quarter and nine-month period have demonstrated, Innocan is bringing strong value for shareholders through our dual focus on our pharma and wellness activities. Chronic pain, which affects over a quarter of the U.S. population, remains one of the most pressing issues in outpatient care today*. Our commitment and solution for chronic pain...
PR Newswire
20/11/2024
Statement of total voting rights and shares forming the company's share capital…
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site :www.inventivapharma.comDateNumber of Shares Outstanding Total voting rights, gross(1) Total voting rights, net(2)November 4, 202487 077 695100 059 05299 938 530 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the...
Nasdaq GlobeNewswire
20/11/2024
Combined General Meeting of December 11, 2024 - Availability of the preparatory…
Daix (France), Long Island City (New York, United States), November 20, 2024– Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”), also known as non-alcoholic steatohepatitis (“ NASH ”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the...
Nasdaq GlobeNewswire
20/11/2024
Altri Comunicati
